EXTX: EXACT Therapeutics publishes shareholder information regarding the delisting

Oslo, Norway, 4 September 2026. EXACT Therapeutics AS ("EXACT" or the "Company")
has today published a shareholder information page on its website in connection
with the upcoming delisting of the Company's shares from Euronext Growth Oslo:
www.exact-tx.com/shareholder-info

The page contains practical information regarding the delisting process, key
dates, shareholder communication and frequently asked questions. The information
document is attached to this announcement. The shares of EXACT will be removed
from trading on Euronext Growth, Oslo as of 12 October 2026. The last day of
trading will be 9 October 2026.
 
For further information, please contact:
John M. Edminson
Chief Financial Officer
EXACT Therapeutics AS
john.edminson@exact-tx.com

About EXACT Therapeutics: 
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are currently traded on Euronext Growth Oslo (EXTX). An
application for delisting of the shares has been approved by Oslo Stock
Exchange, and last day of trading is 9 October, 2026. Further information may be
found here: www.exact-tx.com
may be\
found here: www.exact-tx.com\